Polymorphism in the ortholog gene of the Plasmodium falciparum K13 gene was investigated in Plasmodium vivax isolates collected in Cambodia. All of them were Sal-1 wild-type alleles except two (2/284, 0.7%), and P. vivax K12 polymorphism was reduced compared to that of the P. falciparum K13 gene. Both mutant allele isolates had the same nonsynonymous mutation at codon 552 (V552I) and were from Ratanak Kiri province. These preliminary data should encourage additional studies for associating artemisinin or chloroquine resistance and K12 polymorphism.
artemisinin plus piperaquine) have been used as first-line treatment for falciparum malaria. For vivax malaria, chloroquine, a drug that also induces oxidative stress (18) , was abandoned in 2012 and replaced by dihydroartemisinin plus piperaquine. This change was based on data from clinical therapeutic efficacy studies (day 28 follow-up, PCR-uncorrected WHO protocol) that showed proportions of treatment failure ranging from 0% to 17.4% (in Ratanak Kiri province, 2010) following a chloroquine regimen, while in the same areas, dihydroartemisinin plus piperaquine was 100% effective (19) . It is worth noting that chloroquine resistance in this area was not fully confirmed due to the lack of blood concentration measures and genotyping data (between the isolates on day 0 and those on the day of recrudescence). Moreover, as no reliable molecular marker associated with P. vivax chloroquine resistance has been identified yet, it remains difficult to assess from clinical studies the antimalarial drug resistance of P. vivax (due to confounding factors, such as relapse, reinfection, or recrudescence).
As P. vivax appears to be highly sensitive to oxidative stress (its tropism in reticulocytes probably reflects this sensitivity), investigations of the polymorphism in the orthologous P. vivax gene of the PF3D7_1343700 kelch propeller domain gene were performed, and the main objective was to assess the proportion of parasites with mutant alleles in our recent collection of venous samples collected from symptomatic individuals with P. vivax malaria from 2011 to 2013 in 6 different health centers.
The alignment of the PF3D7_1343700 sequence with the P. vivax reference Sal-1 genome identified an orthologous gene located on chromosome 12 (PVX_083080, named K12 here). A nested PCR approach was designed to amplify the K12 propeller domain (from codons 370 to 702; Fig. 1 ) using the primers F-K12_P1 (5=-ATCCAA CAGCATTTCCAACT-3=) and R-K12_P1 (5=-CAATTAAAACGGA ATGTCCA-3=) for the outer PCR and F-K12_P2 (5=-ACCACGTGA CGAGGGATAAG-3=) and R-K12_P2 (5=-AAAACGGAATGT CCAAATCG-3=) for the inner PCR. Briefly, parasite DNA was extracted from whole blood using the QIAamp DNA blood minikit (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions. The parasite species was confirmed by real-time PCR, as described by Canier et al. (20) . The first round of PCR amplification was performed with a 20-l reaction mixture containing 5 l DNA, 0.25 M each primer, 2.5 mM MgCl 2 , and 0.25 l HOT FIREPol DNA polymerase (Solis BioDyne, Tartu, Estonia) under the following conditions: 95°C for 15 min, followed by 20 cycles at 95°C for 30 s, 58°C for 60 s, and 72°C for 130 s, and a final extension at 72°C for 10 min. Nested PCR amplifications were performed in a 20-l reaction buffer with 5 l of the primary PCR products (10-fold diluted), 0.25 M each primer, 2.5 mM MgCl 2 , and 0.25 l HOT FIREPol DNA polymerase under the following conditions: 95°C for 15 min, followed by 35 cycles at 95°C for 30 s, 62°C for 60 s, and 72°C for 90 s, and a final extension at 72°C for 10 min. Sequencing of the PCR products was performed by Macrogen (Seoul, South Korea), and sequences were aligned against the Sal-1 reference sequence (PVX_083080) using MEGA6. All alignments were manually verified.
A total of 284 Cambodian P. vivax isolates were selected and sequenced (Fig. 2) . All but two (0.7%) sequences were interpretable and were Sal-1 wild-type alleles. The two isolates, collected in 2013 in Ratanak Kiri province in eastern Cambodia, were carrying the same nonsynonymous mutation at codon 552 (V552I) and showed a reduced polymorphism in the P. vivax kelch propeller domain ( Fig. 1) (18) .
The proportions of P. vivax K12 and P. falciparum K13 mutant alleles in samples collected during the same period showed a significantly higher frequency (P Ͻ 10 Ϫ6 ) in Pailin province (western Cambodia) for P. falciparum K13 (95.0% [95% confidence interval (CI), 88.0% to 99.0%]) than for P. vivax K12 (0% [95% CI, 0% to 4.0%]), while the frequencies were similar (P ϭ 0.66) in Ratanak Kiri province (6.0% [95% CI, 1.0% to 19.0%] for P. falciparum K13 versus 3.7% [95% CI, 0.4% to 13 .4%] for the P. vivax K12). These data seem to indicate that artemisinin drug pressure in western Cambodia is not selecting the P. vivax K12 mutation, contrary to what we have observed with P. falciparum K13. However, as we have never observed artemisinin-resistant P. vivax parasites in this area, we cannot rule out its role in artemisinin resistance.
Regarding chloroquine resistance, the two K12 mutant alleles were observed in Ratanak Kiri province, where chloroquine resistance is quite frequent. As no resistant phenotype was available for these two isolates (no ex vivo drug susceptibility assay and no in vivo follow-up of the patients), no association between polymorphism in the K12 propeller domain and chloroquine resistance can be assessed.
Given the high degree of conservation of the protein sequence between different Plasmodium species, it is intriguing to detect those two mutants. However, it must be pointed out that (i) the replacement of the valine at codon 552 by an isoleucine is not a major protein change (both are nonpolar branched-chain amino acids), and (ii) isoleucine is found at this position in 3 mouse parasite Kelch sequences (Fig. 1) .
In conclusion, although we were limited by a lack of clinical and in vitro data, our study presents, for the first time, polymorphism in the orthologous P. vivax gene of the PF3D7_1343700 kelch propeller domain gene compared to that of P. falciparum K13. These preliminary data should encourage additional studies on this gene that aim to associate artemisinin or chloroquine resistance based on clinical or in vitro phenotypes to K12 propeller domain protein polymorphism, especially in Indonesia, East Timor, Papua New Guinea, and South America (Guyana, Peru, and Brazil), where chloroquine resistance is frequent (21) .
